Updated on June 4, 2026 · Published by PatSnap Open Intelligence Team

You’ve designed a promising antibody sequence, and your PI wants to know if it’s clear for development before you invest another month in validation. Right now, that means switching between NCBI BLAST, Espacenet, and a spreadsheet to manually cross-reference hits — a workflow that turns a 20-minute question into a half-day project. This guide shows you how to run the same search in a single AI conversation, getting patent-grounded results without leaving your workspace.

You’re running a VH sequence through NCBI BLAST to check for prior art. The results come back with 50+ hits across GenBank, but none of them tell you which sequences appear in patent claims, who owns them, or whether the patents are active. You export the IDs, open Espacenet in another tab, and start searching assignees one by one. By the time you’ve checked ten hits, your next meeting starts, and you’re nowhere near a complete picture.The problem isn’t the quality of free tools — it’s that no single tool connects sequence similarity to patent metadata. BLAST finds homologs but doesn’t parse patent documents. Espacenet searches patents but doesn’t run BLAST-style alignments. You’re forced to be the integration layer, manually stitching together results that should arrive as a unified answer.Model Context Protocol (MCP) connectors solve this by letting AI assistants query specialized databases live during a conversation. This guide uses PatSnap Biology Modality MCP — built by PatSnap, indexing 208M+ patents and 1.4B+ biosequences. You ask questions in plain language; the MCP runs the search behind the scenes and returns results grounded in live patent data, all without leaving your AI environment.This guide covers:

• Running sequence similarity searches that return patent numbers, assignees, and claim status in one query
• Extracting all sequences from a specific patent to check your design against filed variants
• Understanding what the results mean for your freedom to operate (FTO) review

How to Search Patents by Antibody Sequence Using Your AI

Add the MCP to any MCP-compatible AI (Claude Desktop, Cursor, Continue.dev, or others), paste your sequence, and ask: “Search for similar sequences in patents — show me identity, assignee, and whether it appears in claims.” The connector runs a BLAST-style alignment against indexed biosequences, filters for patented hits, and returns results ranked by percent identity and query coverage.The output shows you which sequences are close enough to matter. For antibody variable domains, anything above 90% identity in the full VH or VL region — or high identity concentrated in CDR-H3 — indicates a potential overlap that your IP team should review. Framework identity alone (the conserved regions outside CDRs) is less concerning, but CDR similarity drives binding specificity and is the sequence space competitors actively claim.

Example output (121aa VH search): Ten hits all showed >92% identity with 100% query coverage and e-values around 10^-72. The top hit (seq 524472305) matched at 93.4% identity. Hit 3 (seq 432296430, also 93.4% identity) appeared explicitly in patent claims. Hit 5 (seq 1492390, 92.6% identity) was annotated as an anti-DLL4 VH domain. Hits 7 and 8 were fusion constructs: a 245aa scFv and a 534aa IgG-CAR. All divergence concentrated in CDR-H3; framework regions matched at >92%.

This tells you several things at once. First, your sequence sits in a crowded patent space — multiple high-identity hits mean the target or binding mode has been explored. Second, one hit appears in claims, which means it’s not just disclosed but actively protected. Third, the anti-DLL4 annotation gives you a functional clue: if you’re targeting the same antigen, you’re in direct sequence space overlap; if not, the similarity might reflect shared framework scaffolds rather than competitive prior art. Fourth, the scFv and CAR-fusion hits show the sequence has been engineered into multiple modality formats, suggesting it’s a well-characterized binder that others have already filed around.The MCP returns this in seconds because it queries a pre-indexed database that maps sequences to patent metadata. You don’t run BLAST, then manually look up each accession number in a separate patent database — the connection is already there. If a sequence is too close for comfort, you can immediately pull the full patent document to see claim scope, priority dates, and whether it’s granted or pending.

What to Look for in Patent Sequence Hits

Not every high-identity hit blocks your work. Patents protect specific sequences and their functional equivalents, but equivalence has limits — a 92% identity match in framework regions with different CDRs might be novel, while 98% identity across all six CDRs is a red flag even if the frameworks differ. Your job at this stage isn’t to make the legal call (that’s for your IP team), but to flag which hits need deeper review.Focus on three data points in your results: identity percentage, which regions match, and whether the sequence appears in claims or just in the specification. Claims define what’s protected; specification sequences might be examples, alternatives, or disclosed-but-not-claimed variants. A 95% match in claims is a stronger signal than a 98% match buried in Example 47 with no claim coverage.For antibody sequences, alignment matters more than raw identity. Two antibodies can share 90% identity but bind completely different epitopes if the divergence is in CDR-H3 (the loop that makes most antigen contacts). Conversely, 85% identity concentrated in all six CDRs with framework differences might indicate the same functional binder expressed in a different host or scaffold. The MCP shows you where the matches fall; you interpret whether that pattern overlaps with your design strategy.Ask your AI: “Which hits show high identity in CDR regions specifically?” The connector can’t parse CDR boundaries automatically (those depend on numbering schemes like Kabat or IMGT), but you can guide the interpretation by giving it your CDR definitions. If you see conserved motifs in the regions you’ve marked as CDRs, that’s the similarity that matters for FTO.Patent families also matter. If the same sequence appears in ten different patent documents, check whether they’re all from the same priority filing (one invention, multiple jurisdictions) or distinct applications (multiple iterations or improvements). The MCP returns patent numbers; you can ask: “Are these patents from the same family or separate filings?” Separate filings might indicate an evolving design space where the assignee is iterating on the original sequence — a sign that the target is competitive and worth monitoring.

How to Extract All Sequences from a Specific Patent

Once you’ve identified a concerning patent from your similarity search, you need to see every sequence it discloses. Competitors often file dozens or hundreds of variants in a single application — consensus sequences, humanized versions, affinity-matured clones, and synthetic constructs designed to cover sequence space around the lead candidate.Ask: “Extract all sequences from patent US10519237B2.” The MCP parses the patent’s sequence listing and returns every protein and nucleotide sequence with its SEQ ID NO, length, and any annotations from the original filing.

Example output (patent US10519237B2): 56 sequences total — 32 proteins and 24 nucleotides. The protein sequences were 15-amino-acid synthetic peptides with single substitutions (e.g., AAAYAAAAAAKAAAA with Y at position 4 and K at position 11, listed as Seq 40249). The nucleotide sequences were 18–24bp DNA oligomers, two annotated as Mus musculus (e.g., CATCCACGTGTTGGCTCA, Seq 29589520).

This patent isn’t claiming full-length antibodies — it’s claiming short peptides and oligonucleotides, likely for an alanine-scan study or a screening library. If your antibody sequence were flagged as similar to one of these patents, this extraction would immediately show you that the similarity is incidental (shared short motifs) rather than structural. You’d deprioritize it and move on. Conversely, if the extraction returned 30 full-length VH sequences with systematic CDR variations, you’d know you’re looking at a patent that intentionally blankets your target space.The extraction also reveals the modality strategy behind the filing. Protein-only patents suggest therapeutic antibodies or peptides. Mixed protein and nucleotide listings might indicate DNA vaccines, CAR-T constructs, or expression vectors. Oligonucleotide-heavy patents could be antisense, siRNA, or aptamers. Understanding what the competitor is claiming helps you assess whether your biologic modality avoids their coverage — an IgG might infringe a disclosed antibody sequence, but a bispecific or ADC conjugate might not if the patent’s claims are narrowly written around monospecific IgG1 formats.

Why This MCP for Biological Sequence Patent Search

You need a tool that connects sequence similarity to patent metadata in the same query. NCBI BLAST’s patent database returns accession numbers but no assignee names, filing dates, or claim text. Espacenet searches patents but doesn’t run sequence alignments. You’re left assembling the full picture manually, which turns every search into a multi-hour project spread across disconnected tools.This MCP runs the BLAST-style search and the patent lookup in one call. You paste a sequence, and the results show identity scores next to patent numbers and assignees. If a hit appears in claims, the connector tells you. If it’s part of a larger family, you can extract the full sequence listing from that patent and compare your design against every disclosed variant — all without switching environments.The database updates daily from WIPO, USPTO, EPO, and CNIPA, so your results reflect filings published this week. In fast-moving therapeutic areas like bispecific antibodies or CAR-T, where new sequences appear in patent filings every month, stale data means you’re checking against an outdated landscape. The connector queries live data, so you’re not caught off-guard by a priority claim filed six months ago that your local BLAST mirror hasn’t indexed yet.Finally, the MCP works inside your existing AI workflow. If you’re already drafting experimental protocols or analyzing alignment results in Claude or Cursor, you don’t need to open another application to run the patent check. You ask the question in the same conversation where you’re designing primers or troubleshooting expression — the MCP handles the search, and you stay in flow. For teams running dozens of sequences through FTO screening, that workflow continuity is the difference between a bottleneck and a scalable process.For additional biologic patent analysis workflows, explore protein family landscape mapping and antibody design space visualization tools.

Try Biological Sequence Patent Search Yourself

Two paths get you the same database — choose based on whether you’re ready to integrate or still evaluating.

Path A — Try in browser, no setup

PatSnap Eureka runs the same searches in a browser. No install, no API key. Best if you’re still evaluating.

Path B — Add the MCP to your AI

1. Get your API key at open.patsnap.com (10,000 free credits, no credit card).
2. Find PatSnap Biology Modality MCP in the marketplace and copy the connection URL.
3. Ask your AI: “Help me add this MCP to my config: [paste URL with API key]” — your AI handles the file path, JSON, and restart.
4. Run a query to see it work: “Search for antibody sequences similar to [your VH sequence] and show patent assignees.” If you see results, you’re set.

Conclusion

Checking whether a biological sequence is already patented no longer requires stitching together BLAST results, patent databases, and spreadsheets. MCP connectors bring sequence similarity and patent metadata into the same query, so you get identity scores, assignee names, and claim status in one answer. For antibody engineers running FTO checks before committing to a candidate, that workflow shift turns a half-day project into a 20-minute conversation. You spend less time managing tools and more time interpreting results — which is where your expertise actually matters.

Note: Information based on publicly available sources as of 2026. Product features may change. Contact PatSnap for current details.

---

Ready to Search Your First Sequence?

Start free — 10,000 credits, no credit card, no subscription.→ Get Your API Key — sign up at open.patsnap.com→ Add the MCP to Your AI — find it in the marketplace→ Try in Browser — PatSnap Eureka, no install

---

Frequently Asked Questions

What is biological sequence patent search?

Biological sequence patent search finds prior art by comparing your protein or nucleotide sequence against sequences disclosed in patents. It uses BLAST-style alignment algorithms to identify similar sequences, then returns the patent documents where those sequences appear, along with metadata like assignee, filing date, and whether the sequence is claimed or just disclosed. This tells you whether your candidate sequence might overlap with existing IP before you invest in development.

How do I check if my antibody sequence is patented?

Paste your VH or VL sequence into a tool that connects sequence similarity to patent metadata. Look for hits with >90% identity across CDR regions, then check whether those sequences appear in patent claims (protected) or just in examples (disclosed but possibly not claimed). High identity in framework regions with divergent CDRs is typically less concerning than near-identical CDR-H3 sequences, which drive binding specificity and are the space competitors actively claim. The MCP in this guide returns these data points in one query; sign up at open.patsnap.com to connect it to your AI, or try PatSnap Eureka in a browser.

What tools do patent attorneys use for sequence search?

Patent attorneys typically use commercial patent databases with integrated sequence search — platforms that combine BLAST-style alignment with legal status tracking. Free tools like NCBI BLAST provide sequence similarity but don’t integrate assignee filtering, claim parsing, or family grouping, so attorneys often use them for preliminary screening and then switch to paid platforms for comprehensive FTO analysis. Some attorneys also reference The Lens PatSeq for open-access patent sequence data.

How does AI improve biologic patent search?

AI assistants with MCP connectors let you ask patent questions in plain language and get results that combine sequence alignment with patent metadata in one answer. Instead of running BLAST in one tool, then manually looking up each hit in a patent database, you ask: “Find patented sequences similar to [sequence] and show me the assignees” — the MCP runs the search and formats the results in your conversation. Sign up at open.patsnap.com to connect the MCP to your AI, or try PatSnap Eureka in a browser with no setup. For broader guidance on patent intelligence workflows, visit the PatSnap resources blog.